Small Cell Lung Cancer (SCLC) Clinical Trials

• Phase I: Patients with ES-SCLC and disease progression after one or more chemotherapy regimens (that included a platinum-based doublet chemotherapy in combination with a PD-L1 inhibitor) according to the local SOC (2L+), unless the patient was ineligible to receive such therapies or was not a candidate for any available standard therapy, according to the investigator's judgement. Prior DLL3 (Delta-like ligand 3) targeted therapy is allowed.

• Phase II: Patients with ES-SCLC who have received a platinum-based doublet chemotherapy in combination with a PD-L1 inhibitor according to local standard of care, unless the patient was ineligible to receive such therapies or was not a candidate for any available standard therapy, as determined by the investigator's judgment. Prior DLL-3 targeted therapy is not allowed.

• Male or female patients must be ≥ 18 years of age.

• Histologically or cytologically confirmed small cell lung cancer (SCLC).

• At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Patients must have an archival tumor tissue available, collected within 6 months prior to screening. If an archival tumor sample, collected within 6 months prior to screening, is not available, patients must be willing to undergo a new tumor biopsy at screening; , however this specimen need not be collected prior to scheduling leukapheresis. If a new biopsy is not medically feasible, exceptions may be considered after documented discussion with the Novartis medical monitor.

• Patient must be deemed suitable by the investigator to undergo the lymphodepletion (LD) regimen.

• Patient must have an apheresis product of non-mobilized cells accepted for manufacturing.